Business, energy, technology, markets and global industry news from Business News Today

Vyvgart Hytrulo

PharmaDeviceNews Vyvgart Hytrulo
A representative image illustrating LB Pharmaceuticals’ LB-102 schizophrenia research as the pivotal NOVA-2 Phase 3 program advances toward an accelerated first-half 2027 readout.
Pharma & Biotech

Zai Lab just secured reimbursement for two growth medicines. Can 2027 reverse its revenue decline?

Zai Lab gains China reimbursement listings for KarXT and VYVGART Hytrulo from January 2027. See how access could reshape product growth.

Read More
Representative image: argenx halts Phase 3 efgartigimod trial in Sjögren’s disease after futility review.
Pharma & Biotech

argenx halts Phase 3 efgartigimod Sjögren’s trial after futility analysis

argenx stops the Phase 3 UNITY efgartigimod trial in Sjögren’s disease for futility despite earlier positive Phase 2 results.

Read More
Representative image: A clinician discusses neuromuscular treatment options with an adult patient as Argenx SE’s expanded Vyvgart approval broadens the FDA label across all adult generalized myasthenia gravis serotypes, strengthening interest in targeted FcRn therapies for autoimmune neurology.
Pharma & Biotech

Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis

Vyvgart now covers all adult gMG serotypes. Argenx gains a wider label, but payers and real-world durability remain the next test.

Read More